Clinical Trial Update: Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab combined with chemotherapy for cross-line treatment in first-line resistant advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN